Recombinant CD22 (Epratuzumab Biosimilar) anticorps

N° du produit ABIN7795107

L’anticorps Humanized Monoclonal anti-CD22 (Epratuzumab Biosimilar) a été validé pour FACS et in vivo. Il convient pour détecter CD22 (Epratuzumab Biosimilar) dans des échantillons de Humain.

Aperçu rapide pour Recombinant CD22 (Epratuzumab Biosimilar) anticorps (ABIN7795107)

Antigène: CD22 (Epratuzumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Conjugué: Cet anticorp CD22 (Epratuzumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-CD22 (Epratuzumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Epratuzumab Biosimilar, CD22 Monoclonal Antibody

Attributs du produit: Epratuzumab Biosimilar uses the same protein sequences as the therapeutic antibody epratuzumab. Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus. Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human CD22

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur CD22 (Epratuzumab Biosimilar)

Antigène: CD22 (Epratuzumab Biosimilar)

Autre désignation: Epratuzumab Biosimilar

Classe de substances: Biosimilar